TJU Taps Perthera for Multi-omic Molecular Diagnostic Analyses
Monday, October 5, 2015
Perthera, a premier personalized medicine service company, and Thomas Jefferson University today announced a collaboration that will provide Perthera’s advanced, multi-omic, molecularly targeted diagnostics and related bioinformatics services and analysis to cancer patients at Thomas Jefferson University Hospitals facilities and affiliates.
Through the collaboration, Thomas Jefferson University Hospitals' oncologists will have the opportunity to evaluate Perthera’s services, which will provide them with a molecular analysis of their patients’ tumors as well as outcomes data, with the long-term goals of not only demonstrating the success of personalized medicine but also enhancing treatment procedures against the disease.
“Perthera will be a strong addition to Jefferson’s formidable and growing efforts to provide patients with personalized and evidence-based care, and will allow our oncologists to more completely and simply understand the nature and progression of any patient’s unique cancer,” said Rebecca O’Shea, senior vice president clinical services of Thomas Jefferson University Hospitals. “We’ve been eager to launch this relationship for some time, and anticipate it making a real difference in our patients’ lives.”
Perthera is the only organization to combine the latest molecular profiling, including genomic, proteomic and phosphoproteomic analysis, with a patient’s medical history and state-of-the-art diagnostic technology, thereby enabling oncologists to deliver precision medicine to treat an individual patient’s unique cancer.
“Our relationship with Thomas Jefferson University [Hospitals] is an exciting one, as the organization’s leadership truly values personalized medicine and the advances it has made to revolutionize the standard of cancer treatment for all patients,” said Andrew Mignatti, president and CEO of Perthera. “Together we’re introducing a new era of personalized cancer therapy by empowering patients and their oncologists with better knowledge than ever existed before about what is happening within the molecular structure of their cancer cells.”
Through the company’s PrecisOn process, Perthera will provide Thomas Jefferson University Hospitals' oncologists with a comprehensive understanding of the molecular architecture of their patients’ tumors. The multiple molecular analyses of each tumor will be integrated into Perthera’s Expert Oncologist system (also known as ExpO), an expert learning database that sources the most current clinical knowledge and research/drug information available, to facilitate analysis of multi-omic molecular profiles in context with the patient’s medical history.
Once testing is complete, Perthera’s Medical Review Panel — which is comprised of disease-specific cancer experts — will analyze and interpret the profiling data to provide actionable therapies and clinical trial options to oncologists and their patients in the final Perthera report. Perthera will then correlate molecular stratification for therapies with patient outcomes, thus providing a unique registry to validate molecular profiling-based therapies.